كليدواژه :
كشاورزي مولكولي , پروتيين هاي نوتركيب , مخاطرات احتمالي , ايمني زيستي
چكيده لاتين :
The large-scale production of recombinant proteins in plants is known as molecular farming. Now, pharmaceutical proteins are the major focus of this emerging technology but plants can also be used to produce food and feed additives, biopolymers, industrial enzymes and research-grade technical proteins such as avidin and ^-glucuronidase. Plants have many advantages in terms of cost, practicality, and safety over traditional expression systems and are emerging as a significant force in the commercial sector. As this technology emerges, there are a number of concerns that have become evident in terms of the potential adverse consequences of using plants as pharmaceutical production platforms. These concerns relate to the direct effects arising from the intended use of the plant-made pharmaceuticals (PMP), the unintended effects that could arise from inadvertent occurrence of PMPs in foods or feeds, and the possible impacts of pharmaceutical crops on the environment, agriculture and economy.
Transgene mixture and recombinant protein toxicity in the environment are biosafety concerns that must be determined. Another biosafety issue is that food and feed crops containing recombinant proteins could get mixed-up with non-transgenic crops or the environment during harvesting, transport, processing and/or waste disposal, and therefore enter the food chain. Finally, all plant-derived recombinant proteins that are administered to human patients must be compared to their natural counterparts and drastically tested for safety.
